Phosphatidic acid, phospholipase D and tumorigenesis

Advances in Biological Regulation

Volumn 54, Issue 1, 2014, Pages 197-206

  Gomez Cambronero, Julian ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDIC ACID; PHOSPHOLIPASE D; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2;

ANIMAL; CARCINOGENESIS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; CARCINOGENESIS; HUMANS; NEOPLASMS; PHOSPHATIDIC ACIDS; PHOSPHOLIPASE D;

EID: 84893414176     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.08.006     Document Type: Review

References (68)

1. Ahn M.J., Park S.Y., Kim W.K., Cho J.H., Chang B.J., Kim D.J., et al. Asingle nucleotide polymorphism in the phospholipase D1 gene is associated with risk of non-small cell lung cancer. Int J Biomed Sci 2012, 8(2):121-128.
2. Buchanan F.G., Mcreynolds M., Couvillon A., Kam Y., Holla V.R., Dubois R.N., et al. Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci USA 2005, 102(5):1638-1642.
3. Chen Q., Hongu T., Sato T., Zhang Y., Ali W., Cavallo J.A., et al. Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis. Sci Signal 2012, 5(249):ra79.
4. Chen Y., Rodrik V., Foster D.A. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005, 24(4):672-679.
5. Chen Y., Zheng Y., Foster D.A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003, 22(25):3937-3942.
6. Cho J.H., Hong S.K., Kim E.Y., Park S.Y., Park C.H., Kim J.M., et al. Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells. Biochim Biophys Acta 2008, 1783(5):912-923.
7. Choi W.S., Hiragun T., Lee J.H., Kim Y.M., Kim H.P., Chahdi A., et al. Activation of RBL-2H3 mast cells is dependent on tyrosine phosphorylation of phospholipase D2 by Fyn and Fgr. Mol Cell Biol 2004, 24(16):6980-6992.
8. Cipriano R., Bryson B.L., Miskimen K.L., Bartel C.A., Hernandez-Sanchez W., Bruntz R.C., et al. Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B 2013.
9. Di Fulvio M., Frondorf K., Gomez-Cambronero J. Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner. Cell Signal 2008, 20(1):176-185.
10. Du G., Altshuller Y.M., Kim Y., Han J.M., Ryu S.H., Morris A.J., et al. Dual requirement for rho and protein kinase C in direct activation of phospholipase D1 through G protein-coupled receptor signaling. Mol Biol Cell 2000, 11(12):4359-4368.
11. Foster D.A. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta 2009, 1791(9):949-955.
12. Foster D.A., Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003, 1(11):789-800.
13. Frohman M.A., Sung T.C., Morris A.J. Mammalian phospholipase D structure and regulation. Biochim Biophys Acta 1999, 1439(2):175-186.
14. Gadir N., Lee E., Garcia A., Toschi A., Foster D.A. Suppression of TGF-beta signaling by phospholipase D. Cell Cycle 2007, 6(22):2840-2845.
15. Gao S., Murakami M., Ito H., Furuhata A., Yoshida K., Tagawa Y., et al. Mutated ras induced PLD1 gene expression through increased Sp1 transcription factor. Nagoya J Med Sci 2009, 71(3-4):127-136.
16. Gomez-Cambronero J. New concepts in phospholipase D signaling in inflammation and cancer. Sci World J 2010, 10:1356-1369.
17. Gozgit J.M., Pentecost B.T., Marconi S.A., Ricketts-Loriaux R.S., Otis C.N., Arcaro K.F. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer 2007, 97(6):809-817.
18. Ha S.H., Kim D.H., Kim I.S., Kim J.H., Lee M.N., Lee H.J., et al. PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 2006, 18(12):2283-2291.
19. Hammond S.M., Jenco J.M., Nakashima S., Cadwallader K., Gu Q., Cook S., et al. Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. JBiol Chem 1997, 272(6):3860-3868.
20. Henkels K.M., Boivin G.P., Dudley E.S., Berberich S.J., Gomez-Cambronero J. Phospholipase D (PLD) drives cell invasion, growth and metastasis in a human breast cancer xenograph model. Oncogene 2013, Epub date 2013/06/12. http://dx.doi.org/10.1038/onc.2013.207.
21. Henkels K.M., Farkaly T., Mahankali M., Segall J.E., Gomez-Cambronero J. Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3). J Mol Biol 2011, 408(5):850-862.
22. Henkels K.M., Mahankali M., Gomez-Cambronero J. Increased cell growth due to a new lipase-GEF (Phospholipase D2) fastly acting on Ras. Cell Signal 2013, 25(1):198-205.
23. Henkels K.M., Peng H.J., Frondorf K., Gomez-Cambronero J. Acomprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation. Mol Cell Biol 2010, 30(9):2251-2263.
24. Hsu Y.L., Hung J.Y., Ko Y.C., Hung C.H., Huang M.S., Kuo P.L. Phospholipase D signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis 2010, 31(4):587-596.
25. Hui L., Rodrik V., Pielak R.M., Knirr S., Zheng Y., Foster D.A. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. JBiol Chem 2005, 280(43):35829-35835.
26. Hui L., Zheng Y., Yan Y., Bargonetti J., Foster D.A. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006, 25(55):7305-7310.
27. Jeon H., Kwak D., Noh J., Lee M.N., Lee C.S., Suh P.G., et al. Phospholipase D2 induces stress fiber formation through mediating nucleotide exchange for RhoA. Cell Signal 2011, 23(8):1320-1326.
28. Kang D.W., Lee J.Y., Oh D.H., Park S.Y., Woo T.M., Kim M.K., et al. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med 2009, 41(9):678-685.
29. Kang D.W., Min Do S. Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. PLoS One 2010, 5(8):e12109.
30. Kang D.W., Min G., Park Do Y., Hong K.W., Min Do S. Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells. Exp Mol Med 2010, 42(8):555-564.
31. Kang D.W., Park M.H., Lee Y.J., Kim H.S., Kwon T.K., Park W.S., et al. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. JBiol Chem 2008, 283(7):4094-4104.
32. Kang D.W., Park M.H., Lee Y.J., Kim H.S., Lindsley C.W., Alex Brown H., et al. Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells. Int J Cancer 2011, 128(4):805-816.
33. Katayama K., Kodaki T., Nagamachi Y., Yamashita S. Cloning, differential regulation and tissue distribution of alternatively spliced isoforms of ADP-ribosylation-factor-dependent phospholipase D from rat liver. Biochem J 1998, 329(Pt 3):647-652.
34. Kato Y., Lambert C.A., Colige A.C., Mineur P., Noel A., Frankenne F., et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. JBiol Chem 2005, 280(12):10938-10944.
35. Kim J., Choi B.H., Jang K.L., Min D.S. Phospholipase D activity is elevated in hepatitis C virus core protein-transformed NIH3T3 mouse fibroblast cells. Exp Mol Med 2004, 36(5):454-460.
36. Kim J.H., Ohba M., Suh P.G., Ryu S.H. Novel functions of the phospholipase D2-Phox homology domain in protein kinase Czeta activation. Mol Cell Biol 2005, 25(8):3194-3208.
37. Kim Y.R., Byun H.S., Won M., Park K.A., Kim J.M., Choi B.L., et al. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC. BMC Cancer 2008, 8:144.
38. Knoepp S.M., Chahal M.S., Xie Y., Zhang Z., Brauner D.J., Hallman M.A., et al. Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol 2008, 74(3):574-584.
39. Lavieri R., Scott S.A., Lewis J.A., Selvy P.E., Armstrong M.D., Alex Brown H., et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg Med Chem Lett 2009, 19(8):2240-2243.
40. Lavieri R.R., Scott S.A., Selvy P.E., Kim K., Jadhav S., Morrison R.D., et al. Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. JMed Chem 2010, 53(18):6706-6719.
41. Lewis J.A., Scott S.A., Lavieri R., Buck J.R., Selvy P.E., Stoops S.L., et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett 2009, 19(7):1916-1920.
42. Luquain C., Singh A., Wang L., Natarajan V., Morris A.J. Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. JLipid Res 2003, 44(10):1963-1975.
43. Mahankali M., Peng H.J., Henkels K.M., Dinauer M.C., Gomez-Cambronero J. Phospholipase D2 (PLD2) is a guanine nucleotide exchange factor (GEF) for the GTPase Rac2. Proc Natl Acad Sci USA 2011, 108(49):19617-19622.
44. Nishikimi A., Fukuhara H., Su W., Hongu T., Takasuga S., Mihara H., et al. Sequential regulation of DOCK2 dynamics by two phospholipids during neutrophil chemotaxis. Science 2009, 324(5925):384-387.
45. Nozawa S., Ohno T., Banno Y., Dohjima T., Wakahara K., Fan D.G., et al. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. JBiol Chem 2005, 280(30):27544-27551.
46. O'Reilly M.C., Scott S.A., Brown K.A., Oguin T.H., Thomas P.G., Daniels J.S., et al. Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells. JMed Chem 2013, 56(6):2695-2699.
47. Oh K.J., Lee S.C., Choi H.J., Oh D.Y., Kim S.C., Min Do S., et al. Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL. JCell Biochem 2007, 101(6):1409-1422.
48. Oshimoto H., Okamura S., Yoshida M., Mori M. Increased activity and expression of phospholipase D2 in human colorectal cancer. Oncol Res 2003, 14(1):31-37.
49. Park M.H., Min Do S. Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res Commun 2011, 412(4):710-715.
50. Park S.H., Chun Y.H., Ryu S.H., Suh P.G., Kim H. Assignment of human PLD1 to human chromosome band 3q26 by fluorescence in situ hybridization. Cytogenet Cell Genet 1998, 82(3-4):224.
51. Park S.H., Ryu S.H., Suh P.G., Kim H. Assignment of human PLD2 to chromosome band 17p13.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 1998, 82(3-4):225.
52. Peng H.J., Henkels K.M., Mahankali M., Marchal C., Bubulya P., Dinauer M.C., et al. The dual effect of Rac2 on phospholipase D2 regulation that explains both the onset and termination of chemotaxis. Mol Cell Biol 2011, 31(11):2227-2240.
53. Riebeling C., Muller C., Geilen C.C. Expression and regulation of phospholipase D isoenzymes in human melanoma cells and primary melanocytes. Melanoma Res 2003, 13(6):555-562.
54. Saito M., Iwadate M., Higashimoto M., Ono K., Takebayashi Y., Takenoshita S. Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep 2007, 18(5):1329-1334.
55. Scott S.A., Selvy P.E., Buck J.R., Cho H.P., Criswell T.L., Thomas A.L., et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 2009, 5(2):108-117.
56. Shen Y., Zheng Y., Foster D.A. Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. Biochem Biophys Res Commun 2002, 293(1):201-206.
57. Shi M., Zheng Y., Garcia A., Xu L., Foster D.A. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett 2007, 258(2):268-275.
58. Sorkin A. Internalization of the epidermal growth factor receptor: role in signalling. Biochem Soc Trans 2001, 29(Pt 4):480-484.
59. Steed P.M., Clark K.L., Boyar W.C., Lasala D.J. Characterization of human PLD2 and the analysis of PLD isoform splice variants. Faseb J 1998, 12(13):1309-1317.
60. Su W., Chen Q., Frohman M.A. Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol 2009, 5(9):1477-1486.
61. Sulzmaier F.J., Valmiki M.K., Nelson D.A., Caliva M.J., Geerts D., Matter M.L., et al. PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D. Oncogene 2012, 31(30):3547-3560.
62. Taves J., Rastedt D., Canine J., Mork D., Wallert M.A., Provost J.J. Sodium hydrogen exchanger and phospholipase D are required for alpha1-adrenergic receptor stimulation of metalloproteinase-9 and cellular invasion in CCL39 fibroblasts. Arch Biochem Biophys 2008, 477(1):60-66.
63. Toschi A., Edelstein J., Rockwell P., Ohh M., Foster D.A. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D. Oncogene 2008, 27(19):2746-2753.
64. Yamada Y., Hamajima N., Kato T., Iwata H., Yamamura Y., Shinoda M., et al. Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer. JMol Med (Berl) 2003, 81(2):126-131.
65. Ye Q., Kantonen S., Gomez-Cambronero J. Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J Mol Biol 2013, 425(4):755-766.
66. Ye Q., Kantonen S., Henkels K.M., Gomez-Cambronero J. A new signaling pathway (JAK-Fes-phospholipase D) that is enhanced in highly proliferative breast cancer cells. J Biol Chem 2013, 288(14):9881-9891.
67. Zheng Y., Rodrik V., Toschi A., Shi M., Hui L., Shen Y., et al. Phospholipase D couples survival and migration signals in stress response of human cancer cells. JBiol Chem 2006, 281(23):15862-15868.
68. Zhong M., Shen Y., Zheng Y., Joseph T., Jackson D., Foster D.A. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2003, 302(3):615-619.